贝伐单抗与雷珠单抗治疗新生血管性青光眼的对照研究

Comparative Study of Bevacizumab and Ranibizumab Treatment for Neovascular Glaucoma

目的探究贝伐单抗联合Ahmed阀植入术与雷珠单抗联合Ahmed阀植入术治疗新生血管性青光眼(neovascular glaucoma,NVG)的临床效果。方法回顾性选取2010年1月-2014年12月间佛山市中医院三水医院收治的新生血管性青光眼患者共78例,均采用Ahmed青光眼房水引流阀植入术。根据患者术前用药情况将其分为对照组(41例)和观察组(37例),对照组注射贝伐单抗,观察组注射雷珠单抗。结果两组患者术后的最佳矫正视力,眼压,抗青光眼药物数目以及新生血管消退等情况较术前均有明显改善(P<0.05),但治疗效果和安全性差异无统计学意义(P>0.05)。结论青光眼房水引流阀植入术联合术前玻璃体腔内注射贝伐单抗或雷珠单抗,均对新生血管性青光眼起到一定的治疗效果,并且疗效和并发症无明显差异。

Objective To explore the bevacizumab Ahmed valve implantation and ranibizumab joint Ahmed valve implantation treatment for neovascular glaucoma（ neovascular glaucoma,NVG） effects and to analyze its clinical value. Methods A total of 78 patients with neovascular glaucoma treated in the hospital from January,2010 to December,2014 were retrospectively analyzed. All patients were treated with Ahmed glaucoma drainage valve implantation. According to preoperative treatment,they were divided into control group（ 41 cases） and observation group（ 37 cases）. Bevacizumab was injected into control growp,and ranibizumab was injected into observation group. Results The postoperative best corrected visual acuity,intraocular pressure,the number of anti-glaucoma drugs and regression of neovascularization were significantly improved compared with preoperative period（ P〈0. 05）,but there is no statistical difference in the effect of treatment and safety,with no statistical significance（ P 〉0. 05）. Conclusion Glaucoma aqueous drainage valve implantation combined with preoperative intravitreal bevacizumab or ranibizumab are capable of neovascular glaucoma,and there is no significant difference in the effect and complications.